Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

recurrent Primary Central Nervous System Lymphoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Recurrent Primary Central Nervous System Lymphoma

Broader topic: Primary Central Nervous System Lymphoma

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Recurrent Primary Central Nervous System Lymphoma

    Study evidence for this setting

    8 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00918333 · Registry condition search · Scope: unclear

    Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT01789255 · Registry condition search · Scope: unclear

    Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT01973062 · Registry condition search · Scope: unclear

    Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT02301364 · Registry condition search · Scope: unclear

    Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

    4 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT02420795 · Registry condition search · Scope: unclear

    Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

    4 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT03038672 · Registry condition search · Scope: unclear

    Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

    6 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT03255018 · Registry condition search · Scope: unclear

    Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT04548648 · Registry condition search · Scope: unclear

    A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice